Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D

Chiara Fabbri, Antonio Drago, Alessandro Serretti

Research output: Contribution to journalArticlepeer-review


The glutamatergic system has been suggested as a modulator of rapid antidepressant response. Thus, 44 glutamatergic genes were selected according to the literature and investigated in 1541 major depressive patients from the STAR*D genome wide dataset. Outcomes of interest were early response (2nd week) and late response (from the 4th to the 14th week) compared to non-response and stability of response through the STAR*D level 1. A complete agglomerative clustering, based on pairwise identity-by-state (IBS) matrix, was applied in order to control for genetic admixture. A chi-square test was employed as exploratory analysis and a logistic regression was employed to corroborate SNPs associated to the outcomes at p

Original languageEnglish
Pages (from-to)612-621
Number of pages10
JournalEuropean Neuropsychopharmacology
Issue number7
Publication statusPublished - Jul 2013


  • Antidepressant
  • Glutamate
  • Major depression
  • Pathway analysis
  • Pharmacogenetics

ASJC Scopus subject areas

  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Biological Psychiatry
  • Neurology
  • Pharmacology


Dive into the research topics of 'Early antidepressant efficacy modulation by glutamatergic gene variants in the STAR*D'. Together they form a unique fingerprint.

Cite this